Danderyd

• Thrombolysis in Factor Xa-inhibitors Trial (SIFT) Recruiting
  2023-509907-34-01 5 2025-03-10 acute ischemic stroke
• Discontinuation of rituximab compared with rituximab maintenance in ANCA-associated vasculitis – a randomized non-blinded controlled trial ( … Recruiting
  2023-508398-10-00 6 2024-12-12 ANCA-associated vasculitis
• Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting
  2023-508162-15-00 5 2024-07-12 Chronic HF and comorbid impairment of kidney function who had a recent
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04 Chronic Obstructive Pulmonary Disease (COPD)
• Preeclampsia Intervention 4 Recruiting
  2022-502707-29-00 5 2024-02-07 Preeclampsia
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting
  2022-500587-35-01 5 2023-07-06 Stroke
• SACK Recruiting
  2022-501600-10-00 5 2023-02-07 Atrial fibrillation and Chronic Kidney Disease stage 5
• FI-3, Fidelia Recruiting
  2024-518243-38-00 5 2022-04-20 Fecal incontinence in female and male patients
• Antibiotic Impregnated Bone Graft to reduce infection in hip replacement - the ABOGRAFT trial Recruiting
  2024-510921-25-00 4 2022-03-18 Prosthetic Joint Infection
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• OPTION – OutPatienT InductiON: Labour induction in an outpatient setting - a multicentre randomized controlled trial Recruiting
  2023-507164-39-00 6 2021-12-01 Induction of labour
• Optimized pharmacologic treatment for broken heart (takotsubo) syndrome Recruiting
  2022-501874-21-00 6 2020-12-15 Takotsubo syndrome
• PiSCATIN - Simvastatin for the treatment of primary sclerosing cholangitis (PSC) - a randomized double-blind, placebo-controlled multicenter … Recruiting
  2024-511053-22-00 4 2020-05-04 Primary sclerosing cholangitis (PSC)
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended recruitment
  2024-518998-33-00 5 2025-07-23 Ulcerative Colitis
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• A phase 2a, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of RBD1016 in participants with chronic hepatitis D viru … Ended recruitment
  2023-509007-33-00 4 2024-08-21 Chronic hepatitis D virus infection
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn … Ended recruitment
  2023-506457-38-00 5 2024-06-05 Chronic kidney disease (CKD) and hypertension.
• A First-In-Human Trial of the novel T cell Immunotherapy pTTL in Patients with Advanced Colorectal Cancer Ended recruitment
  2024-512296-13-00 1 2023-04-03 colorectal cancer
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended recruitment
  2023-506994-36-00 5 2018-10-11 Ulcerative Colitis
• Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction SPIRRIT-HFpEF Ended recruitment
  2024-517448-79-00 5 2017-11-23 Heart failure with preserved ejection fraction
• A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea … Ended recruitment
  2023-506399-28-00 5 2017-11-08 Crohn's Disease
• A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke Halted
  2023-506178-11-00 5 2025-11-11 Acute ischemic stroke
• A study to learn how safe starting vericiguat at a dose of 5 milligrams is in participants with chronic heart failure with reduced ejection … Ended
  2023-507682-25-00 4 2024-05-13 Chronic heart failure with reduced ejection fraction

Showing 25–48 of 56 trials